cetrorelix 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
gonadotropin-releasing-hormone (GnRH) inhibitors, peptides	583	120287-85-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: cetrotide cetrorelix acetate cetrorelix	LHRH antagonist Molecular weight: 1431.06 Formula: C70H92ClN17O14 CLOGP: -3.09 LIPINSKI: 3 HAC: 31 HDO: 17 TPSA: 495.67 ALOGS: -5.31 ROTB: 38

Molecule

Description

Molfile Inchi Smiles

Synonyms:

cetrotide
cetrorelix acetate
cetrorelix

LHRH antagonist

Molecular weight: 1431.06
Formula: C70H92ClN17O14
CLOGP: -3.09
LIPINSKI: 3
HAC: 31
HDO: 17
TPSA: 495.67
ALOGS: -5.31
ROTB: 38

Drug dosage:

Dose	Unit	Route
0.25	mg	P

ADMET properties:

Show entries

Search:

Property	Value	Reference
S (Water solubility)	8 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	3 %	Benet LZ, Broccatelli F, Oprea TI
t_half (Half-life)	12 hours	Lombardo F, Berellini G, Obach RS
CL (Clearance)	1.20 mL/min/kg	Lombardo F, Berellini G, Obach RS
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
Vd (Volume of distribution)	0.39 L/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.14 %	Lombardo F, Berellini G, Obach RS

Showing 1 to 7 of 7 entries

Previous1Next

Approvals:

Show entries

Search:

Date	Agency	Company
April 12, 1999	EMA	MERCK EUROPE B.V.
April 20, 2006	PMDA	NIPPON KAYAKU CO., LTD.
Aug. 11, 2000	FDA	EMD SERONO INC

Showing 1 to 3 of 3 entries

Previous1Next

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Ovarian hyperstimulation syndrome	824.28	56.34	119	621	3895	63484387
Premature ovulation	149.80	56.34	15	725	7	63488275
Blood luteinising hormone increased	135.23	56.34	16	724	93	63488189
Ascites	95.46	56.34	30	710	40698	63447584
Ovarian disorder	60.77	56.34	10	730	720	63487562
Abortion spontaneous	60.02	56.34	22	718	47173	63441109
Pelvic fluid collection	58.95	56.34	10	730	866	63487416

Showing 1 to 7 of 7 entries

Previous1Next

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Ovarian hyperstimulation syndrome	852.41	67.81	114	474	3457	79740343
Premature ovulation	124.42	67.81	12	576	7	79743793
Blood luteinising hormone increased	95.53	67.81	12	576	199	79743601
Ascites	86.87	67.81	29	559	75533	79668267

Showing 1 to 4 of 4 entries

Previous1Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	H01CC02	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES HYPOTHALAMIC HORMONES Anti-gonadotropin-releasing hormones
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:59229	GnRH antagonists
FDA EPC	N0000175839	Gonadotropin Releasing Hormone Receptor Antagonist
FDA MoA	N0000175084	Gonadotropin Releasing Hormone Receptor Antagonists
FDA PE	N0000008638	Decreased GnRH Secretion
MeSH PA	D005300	Fertility Agents, Female
MeSH PA	D006727	Hormone Antagonists
MeSH PA	D012102	Reproductive Control Agents

Showing 1 to 9 of 9 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID
Prevention of premature ovulation during controlled ovarian stimulation	indication	732970000
Premature Luteinizing Hormone Surges	indication
Prevention of premature ovulation	indication
Acute nephropathy	contraindication	58574008
Pregnancy, function	contraindication	289908002
Breastfeeding (mother)	contraindication	413712001

Showing 1 to 6 of 6 entries

Previous1Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Show entries

Search:

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.65	acidic
pKa10	5.35	Basic
pKa2	12.09	acidic
pKa3	12.45	acidic
pKa4	13.01	acidic
pKa5	13.29	acidic
pKa6	13.37	acidic
pKa7	13.67	acidic
pKa8	13.71	acidic
pKa9	10.75	Basic

Showing 1 to 10 of 10 entries

Previous1Next

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
EQ 0.25MG BASE/VIAL	CETRORELIX ACETATE	TEVA PHARMS INC	A215737	Aug. 12, 2022	RX	POWDER	SUBCUTANEOUS	April 22, 2023	COMPETITIVE GENERIC THERAPY

Showing 1 to 1 of 1 entries

Previous1Next

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Gonadotropin-releasing hormone receptor	GPCR	P30968	GNRHR_HUMAN	ANTAGONIST	Ki	8.80		CHEMBL	CHEMBL
Lutropin-choriogonadotropic hormone receptor	GPCR	P22888	LSHR_HUMAN					WOMBAT-PK

Showing 1 to 2 of 2 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
007799	NDDF
007800	NDDF
1190	IUPHAR_LIGAND_ID
130143-01-0	SECONDARY_CAS_RN
15671	MMSL
25074887	PUBCHEM_CID
259338	RXNORM
326083001	SNOMEDCT_US
362200	MMSL
37942	MMSL

Showing 1 to 10 of 24 entries

Previous1 2 3Next

Pharmaceutical products:

None